Dong-A ST Co., Ltd. is a South Korean pharmaceutical company headquartered in Goyang, Gyeonggi Province, South Korea, specializing in novel pharmaceuticals, biosimilars, and advanced drug delivery systems for CNS disorders and other therapeutic areas[1]. The company is a subsidiary of Dong-A Pharmaceutical Co., Ltd., one of Korea's oldest and most established pharmaceutical companies, with a history dating back to 1932.
| Attribute | Value |
|---|---|
| Founded | 1932 (original company) |
| Headquarters | Goyang, Gyeonggi Province, South Korea |
| Parent | Dong-A Pharmaceutical Co., Ltd. |
| Stock | KRX: 170900 |
| Website | donga-st.co.kr |
| Employees | 1,500+ |
| Focus Areas | CNS, oncology, cardiovascular, immunology |
Dong-A ST focuses on developing and marketing innovative medicines across multiple therapeutic areas:
The company has invested significantly in biosimilar development:
Dong-A ST maintains advanced drug delivery platforms:
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| DA-3501 | Long-acting dopamine agonist | Phase 2 | Active |
| DA-3201 | COMT inhibitor | Phase 1 | Completed |
| DA-4001 | Alpha-synuclein antibody | Discovery | Research |
DA-3501 is the company's lead Parkinson's program—a novel long-acting dopamine agonist designed to provide extended symptom control with reduced dosing frequency. The Phase 2 program is actively recruiting patients to evaluate efficacy and safety.
DA-3201 is a COMT (catechol-O-methyltransferase) inhibitor that works alongside levodopa to extend its duration of action. Phase 1 studies have been completed, demonstrating safety and tolerability.
DA-4001 represents Dong-A ST's entry into disease-modifying Parkinson's therapy—an alpha-synuclein antibody targeting the pathological protein aggregation seen in Parkinson's disease.
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| DA-4501 | Amyloid-beta antibody | Phase 1 | Recruiting |
| DA-4601 | Neuroprotective agent | Preclinical | Research |
DA-4501 is an amyloid-beta targeting monoclonal antibody in Phase 1 clinical trials, designed to reduce amyloid plaque burden in Alzheimer's disease patients.
DA-4601 is a neuroprotective agent in preclinical development, targeting multiple pathways involved in neuronal survival and function.
| Product | Indication | Description |
|---|---|---|
| Tremycin | Parkinson's disease | Levodopa/carbidopa combination therapy |
| Duxenil | Cognitive enhancement | Nootropic agent for memory and cognition |
| Stelaton | Parkinson's disease | Dopamine agonist for motor symptoms |
Dong-A ST's NDDS platform enables:
The company has established biosimilar capabilities:
Research into cell therapy approaches:
Dong-A ST has established international collaborations to expand market access and enhance R&D capabilities:
| Partner | Focus Area |
|---|---|
| Pfizer | Licensing agreement for selected products |
| Merck KGaA | Distribution partnership in select markets |
| Seoul National University | Academic research collaboration |
| Yonsei University | Clinical research partnership |
The company actively pursues global market expansion:
Dong-A ST maintains sophisticated manufacturing facilities:
All facilities comply with international GMP standards (FDA, EMA, Korean MFDS).
Dong-A ST is recognized as one of Korea's leading pharmaceutical companies: